Literature DB >> 25110257

The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease.

Parambir S Dulai1, Corey A Siegel2.   

Abstract

In this review, the available data regarding the risk of lymphoma, skin cancers, and other malignancies associated with biological agents that are approved and those under investigation for use in inflammatory bowel disease (IBD) are highlighted. How providers may approach the use of these agents in various clinical scenarios is discussed. This review may help providers better understand the true risk of malignancy associated with these agents, thereby leading to an enhanced communication process with patients with IBD when therapeutic decisions are being made.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biologics; Inflammatory bowel disease; Lymphoma; Malignancy; Skin cancer

Mesh：

Substances：

Year:  2014        PMID： 25110257     DOI： 10.1016/j.gtc.2014.05.010

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  17 in total

Review 1.  Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.

Authors:  Clara Abraham; Parambir S Dulai; Séverine Vermeire; William J Sandborn
Journal:  Gastroenterology       Date:  2016-10-22       Impact factor: 22.682

2.  Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases.

Authors:  Taku Kobayashi; Eri Udagawa; Toshifumi Hibi
Journal:  Digestion       Date:  2022-01-04       Impact factor: 3.216

3.  TNFα Augments Cytokine-Induced NK Cell IFNγ Production through TNFR2.

Authors:  Wagdi Almishri; Tania Santodomingo-Garzon; Tyson Le; Danuta Stack; Christopher H Mody; Mark G Swain
Journal:  J Innate Immun       Date:  2016-08-25       Impact factor: 7.349

Review 4.  Next-Generation Therapeutics for Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; William J Sandborn
Journal:  Curr Gastroenterol Rep       Date:  2016-09

Review 5.  Acute severe ulcerative colitis: latest evidence and therapeutic implications.

Authors:  Parambir S Dulai; Vipul Jairath
Journal:  Ther Adv Chronic Dis       Date:  2017-11-24       Impact factor: 5.091

Review 6.  Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Maneesh Dave; Kathan Mehta; Jay Luther; Anushka Baruah; Allan B Dietz; William A Faubion
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

Review 7.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; Siddharth Singh; Niels V Casteele; Brigid S Boland; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

8.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Authors:  Magali Lemaitre; Julien Kirchgesner; Annie Rudnichi; Fabrice Carrat; Mahmoud Zureik; Franck Carbonnel; Rosemary Dray-Spira
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

Review 9.  Golimumab (anti-TNF monoclonal antibody): where we stand today.

Authors:  Ana Teresa Melo; Raquel Campanilho-Marques; João Eurico Fonseca
Journal:  Hum Vaccin Immunother       Date:  2020-12-28       Impact factor: 3.452

10.  Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.

Authors:  Gary R Lichtenstein; Gerhard Rogler; Matthew A Ciorba; Chinyu Su; Gary Chan; Ronald D Pedersen; Nervin Lawendy; Daniel Quirk; Chudy I Nduaka; Andrew J Thorpe; Julian Panés
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.